The Effect of Hypertension Medications on Renal Blood Flow Measurements in Healthy Males (MK-0000-127)
- Registration Number
- NCT00856960
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Brief Summary
This study will evaluate the effect of Aliskiren and Losartan on renal blood flow using PAH clearance, PC MRA and ASL MRI methodologies.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Male
- Target Recruitment
- 12
Inclusion Criteria
- Subject is in generally good health
- Subject is willing to avoid unaccustomed strenuous exercise during the study
- Subject agrees to consume ONLY the study-specified diet during all domiciled periods
- Subject has been a non-smoker for at least 3 months prior to study
- Subject will refrain from smoking or using any tobacco products during the study
- Subject agrees to refrain from consuming alcohol or caffeine during the domiciled periods and agrees to limit alcohol and caffeine consumption throughout the study
Exclusion Criteria
- Subject has contraindication to MRI scans
- Subject has a history of stroke, seizure, or major neurological disorders
- Subject uses illicit drugs or has a history of drug/alcohol abuse
- Subject has had major surgery, has donated or lost 1 unit of blood, or has been in another investigational study in the last 4 weeks
- Subject has a history of multiple and/or severe allergies to drugs or food
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- CROSSOVER
- Arm && Interventions
Group Intervention Description 1 Aliskiren Aliskiren 600 mg 2 Aliskiren Aliskiren 150 mg
- Primary Outcome Measures
Name Time Method change in renal plasma flow as measured by PAH clearance and on renal blood flow as measured by ASL MRI after single-dose Aliskiren 2-5 hours post dose of study drug
- Secondary Outcome Measures
Name Time Method change in renal plasma flow as measured by PAH clearance and on renal blood flow as measured by ASL MRI after single-dose Losartan 2-5 hours post dose of study drug